产品详情
查看大图

  • 产品名称：Anti-ARHGAP45 antibody (STJA0009676)

  • 产品型号：STJA0009676
  • 产品厂商：ST john's laboratory
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
Anti-ARHGAP45 antibody (STJA0009676)
详情介绍：
Host: Rabbit
Applications: WB
Reactivity: Human/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Rho GTPase-activating protein 45 is suitable for use in Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: ARHGAP45
Gene ID: 23526
Uniprot ID: HMHA1_HUMAN
Specificity: This antibody detects endogenous levels of HMHA1 at Human, Mouse
Immunogen: Synthesized peptide derived from human HMHA1
Function Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.
Protein Name Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1
Mhag Ha-1
Database Links Reactome: R-HSA-6798695
Reactome: R-HSA-8980692
Reactome: R-HSA-9013148
Reactome: R-HSA-9013149
Cellular Localisation Cytoplasm
Cell Projection
Ruffle Membrane
Alternative Antibody Names Anti-Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1 antibody
Anti-Mhag Ha-1 antibody
Anti-ARHGAP45 antibody
Anti-HMHA1 antibody
Anti-KIAA0223 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
姓名：
电话：
您的需求：
 

沪公网安备 31011002002624号